Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by 2019champson Nov 30, 2021 11:45am
98 Views
Post# 34180410

RE:RHT Financials Report Huge Revenue Increase of 192%....

RE:RHT Financials Report Huge Revenue Increase of 192%....I got this from yahoo finance: So, $1.6M in revenue in the quarter AFTER she said they'd hit a run rate of $1.5M/quarter and would have rapidly increasing revenue = missed promise. Share-based compensation, which she said would stop, has continued. During the quarter they issued almost 9M new shares, and then another 5M after the quarter = share dilution = missed promise. She said they'd be profitable in the quarter ending 6/30, but in this quarter ending in Sept they lost another $4.2M = missed promise. She said they'd be cash flow positive in the 3/31 quarter, but this quarter again were negative $2.1M (which is much more than a year ago when they were negative $600K in cash flow, so that's getting worse actually) = missed promise. She also talked about hitting $11M in revenue in 2021. So far in 3 quarters they are just below $2.5M in revenue. That sounds like it will be another missed promise. Sounds like a company going bankrupt to me lmao. Now screw off
<< Previous
Bullboard Posts
Next >>